Novartis’ Sandoz to appeal US district court ruling on biosimilar Erelzi

This article was originally published here

The United States District Court of New Jersey gave ruling against Sandoz over the validity of the two patents that describe and claim Enbrel and the methods for

The post Novartis’ Sandoz to appeal US district court ruling on biosimilar Erelzi appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply